Active immunotherapy: Current state of the art in vaccine approaches for NHL Journal Article
| Author: | Palomba, M. L. |
| Article Title: | Active immunotherapy: Current state of the art in vaccine approaches for NHL |
| Abstract: | Immune therapy of cancer is a rapidly evolving field, with long-deserved successes now finally achieved. As new pathways triggered by the immune synapsis are elucidated, and new molecules responsible for immune checkpoints are being discovered, it is becoming clear that vaccination against a single antigen aided by non-specific immune stimulation is not sufficient for an efficient, long term, immune response. Though lymphoma is a highly curable malignancy, there is still a subset of patients that is at very high risk of disease relapse even after successfully completing chemotherapy or a stem cell transplant. Patients with minimal residual disease are particularly suitable for vaccination. Over the past 3 decades, the classic model of lymphoma-specific idiotype vaccine has evolved and recent data on vaccination with nonspecific oligodeoxynucleotides has provided very encouraging results. Furthermore, the introduction of checkpoint blockade via agonist or antagonist monoclonal antibodies holds the promise of significant improvement in the efficacy of future vaccines.What follows is a brief summary of the historical highlights in lymphoma immunotherapy as well as an update on the most recently published clinical trials and a look at future developments. © Springer Science+Business Media, LLC 2012. |
| Keywords: | treatment outcome; prednisone; cancer recurrence; doxorubicin; drug efficacy; clinical trials as topic; drug targeting; disease free survival; chemotherapy, adjuvant; rituximab; cd8 antigen; antigen expression; cd8+ t lymphocyte; dendritic cell vaccine; ipilimumab; unindexed drug; cancer immunotherapy; progression free survival; mantle cell lymphoma; pain; granulocyte macrophage colony stimulating factor; cyclophosphamide; vincristine; stem cell transplantation; high risk patient; monoclonal antibody; fever; injection site reaction; cd20 antigen; antigen presentation; nonhodgkin lymphoma; immune response; immunotherapy; gamma interferon; cancer vaccines; minimal residual disease; lymphoma, non-hodgkin; cancer testis antigen; ny eso 1 antigen; cpg oligodeoxynucleotide; vaccination; lymphoma; melanoma antigen; immunostimulation; large cell lymphoma; cytokine release; glucocorticoid induced tumor necrosis factor receptor; follicular lymphoma; marginal zone lymphoma; injection site erythema; t lymphocyte activation; receptor binding; oligodeoxynucleotide; cd27 antigen; mifamurtide; keyhole limpet hemocyanin; adjuvants; programmed death 1 receptor; randomized controlled trial (topic); toll like receptor 9; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); antibodies, blocking; injection site swelling; active immunization; cd40 antigen; idiotypic antibody; cd137 antigen; injection site induration; b lymphocyte antigen; checkpoint blockade; immunotherapy, active; cd40 ligand monoclonal antibody; immunoglobulin idiotypes; cell cycle checkpoints; idiotype; lymphoma vaccine |
| Journal Title: | Current Oncology Reports |
| Volume: | 14 |
| Issue: | 5 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2012-10-01 |
| Start Page: | 433 |
| End Page: | 440 |
| Language: | English |
| DOI: | 10.1007/s11912-012-0255-7 |
| PROVIDER: | scopus |
| PMCID: | PMC3441177 |
| PUBMED: | 22843515 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "CODEN: CORUA" - "Source: Scopus" |
